Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated significant growth in its EsoGuard product, with a marked increase in processed tests from 2,420 in Q1 to 3,147 in Q2, indicating strong market traction and potential for continued expansion. The company is well-positioned within the medical technology sector, with multiple products still in early commercialization stages but expected to grow substantially in the coming years, reflecting a promising pipeline for revenue generation. Furthermore, the entry of competitors into the market underscores the substantial opportunity available for PAVmed, enhancing the appeal of its offerings and signaling the potential for acquisition interest.

Bears say

PAVmed Inc. reported a pro forma net loss of $5.4 million, reflecting a deterioration from previous estimates and underscoring persistent financial challenges. The company's testing volume for its flagship product, EsoGuard, decreased in Q3, indicating potential issues with demand or market penetration. Additionally, the significant risks associated with liquidity, regulatory approvals, and commercialization factors further contribute to a negative outlook for the stock, exacerbated by reduced revenue estimates for 2024.

PAVmed (PAVM) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Buy based on their latest research and market trends.

According to 4 analysts, PAVmed (PAVM) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.